World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access
Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc
Journal website https://www.wjon.org

Original Article

Volume 14, Number 6, December 2023, pages 529-539

Efficacy of First-Line Immunotherapy Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients With Different Brain Metastases Status: A Systematic Review and Meta-Analysis

Figures

Figure 1.
Figure 1. Flowchart illustrating trial selection.
Figure 2.
Figure 2. Risk of bias assessment for the included trials.
Figure 3.
Figure 3. Forest plot displaying hazard ratios (HRs) for comparing progression-free survival between immunotherapy combined with chemotherapy and chemotherapy alone. (a) Patients with brain metastases. (b) Patients without brain metastases. CI: confidence interval.
Figure 4.
Figure 4. Sensitivity analysis for progression-free survival. (a) Patients with brain metastases. (b) Patients without brain metastases. HR: hazard ratio; CI: confidence interval.
Figure 5.
Figure 5. Assessment of publication bias for progression-free survival. (a) Patients with brain metastases. (b) Patients without brain metastases.
Figure 6.
Figure 6. Forest plot illustrating hazard ratios for overall survival between immunotherapy combined with chemotherapy and chemotherapy alone. (a) Patients with brain metastases. (b) Patients without brain metastases. HR: hazard ratio; CI: confidence interval.
Figure 7.
Figure 7. Sensitivity analysis for overall survival. (a) Patients with brain metastases. (b) Patients without brain metastases. HR: hazard ratio; CI: confidence interval.
Figure 8.
Figure 8. Assessment of publication bias for overall survival. (a) Patients with brain metastases. (b) Patients without brain metastases.

Table

Table 1. Characteristics of Included Trials
 
TrialsYearAreaPhaseTreatmentsBrain metastases
YesNo
EP: etoposide + cisplatin; EC: etoposide + carboplatin; q3w: once every 3 weeks.
CA184-1562016Worldwide3Ipilimumab q3w × 4 + EP/EC q3w × 455423
EP/EC q3w × 645431
KEYNOTE-6042020Worldwide3Pembrolizumab + EP/EC q3w × 433195
EP/EC q3w × 422203
ASTRUM-0052022Worldwide3Serplulimab + EC q3w × 450339
EC q3w × 428168
IMpower-1332018Worldwide3Atezolizumab + EC q3w × 417184
EC q3w × 418184
CASPIAN-durva2019Worldwide3Durvalumab + EP/EC q3w × 628240
EP/EC q3w × 627242
CASPIAN-tremeli + durva2020Worldwide3Durvalumab + tremelimumab + EP/EC q3w × 638230
EP/EC q3w × 627242
CAPSTONE-12022China3Adebrelimab + EC q3w × 4 - 65225
EC q3w × 4 - 65227